The Chinese equivalent of the FDA internationally approved a new drug shown to be effective at managing mild-to-moderate symptoms of Alzheimer’s disease after a rigorous, 17-year, 3-Phase clinical trial which yielded positive results.
The announcement paves the way for the new drug, designated GV-971 and marketed as Jiuyiyi, to be prescribed immediately in China and increases the likelihood it may be approved in Europe and North America soon.